The federal government said GenomeDx billed Medicare for its Decipher Biopsy prostate cancer genome classifier on behalf of patients who didn't need the test.
The DOJ alleged Biotheranosics promoted and performed its Breast Cancer Index test for patients who had not been in remission for five years and who had not been taking tamoxifen.
The settlement requires that Curiox refrain from saying that one of its products has equivalent or better sensitivity and reproducibility than a Luminex system.
The deal ends an investigation by the SEC into certain accounting practices by Alere's foreign subsidiaries. The company also consented to a cease-and-desist order.
Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.
